MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.21
−0.21%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -77.2%
- EBIT
- -82.6%
- EPS
- -19.1%
- Free cash flow
- +28.0%
- Operating cash flow
- +28.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +42.9%
- EPS
- +42.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.0%
- EBIT
- +11.3%
- Net income
- +13.0%
- EPS
- +37.4%
- Free cash flow
- +14.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026